AstraZeneca’s $80B sales goal by 2030 reflects industry’s penchant for long-term bets

This week, AstraZeneca embarked on a path to bring in $80 billion in sales by 2030. Achieving the ambition will require many moving parts to come together by then, most importantly a series of cancer drugs the company anticipates will achieve individual blockbuster status in the next few years.